BioWorld

Nov. 7, 2006

Adolor Suffers Setback On FDA Request For More Entereg Data

The FDA delayed approving Adolor Corp.'s Entereg (alvimopan) for postoperative ileus yet again, pending additional safety data, causing the company's shares to tumble by 44.8 percent on Monday. (BioWorld Today) Read More

Biotech Rides Wave Of M&A; Licensing Deals Remain Hot

Ambit, Cephalon Enter Potential $250M Deal On Kinase Inhibitors

Abbott Paying $3.7B For Kos In Move To Bolster Lipids Portfolio

Celgene Raises $1B As Part Of Addition To S&P 500 Index

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...